DOI : 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Issue 05 · Volume 55 · May 2017 DOI: 10.1055/s-007-33919

Österreichische Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH)
50. Jahrestagung & 28. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH)
Linz, 08.–10.06.2017

Kongresspräsident: Prim. Univ.-Prof. Dr. Rainer Schöfl Kongresssekretäre: Univ.-Prof. Dr. Christoph Högenauer, Prim. Priv.-Doz. Dr. Andreas Maieron Fortbildungskurs: Univ.-Prof. Dr. Peter Ferenci, Prim. Univ.-Prof. Dr. Rainer Schöfl
Abstracts (HTML) List of Authors
A37
Blesl, A; Horvath, A; Jüngst, C; Leber, B; Schmerböck, B; Tawdrous, M; Stiegler, P; Rainer, F; Spindelböck, W; Fickert, P; Lammert, F; Stadlbauer, V: Increased gut permeability and changes of the gut microbiota in secondary sclerosing cholangitis of critically ill patients (SSC-CIP)
A38
Bucsics, TA; Grasl, B; Schwabl, P; Mandorfer, M; Dmitrieva, J; Peck-Radosavljevic, M; Trauner, M; Sieghart, W; Ferlitsch, A; Reiberger, T: The novel point shear-wave elastography method ElastPQ® is accurate for non-invasive evaluation of liver fibrosis and portal hypertension
A39
Bucsics, TA; Hoffmann, S; Grünberger, J; Schoder, M; Matzek, W; Mandorfer, M; Schwabl, P; Ferlitsch, A; Peck-Radosavljevic, M; Trauner, M; Karner, J; Karnel, F; Reiberger, T: ePTFE-TIPS versus repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis
A40
Chromy, D; Schwabl, P; Bucsics, T; Scheiner, B; Strassl, R; Mayer, F; Aichelburg, M; Grabmeier-Pfistershammer, K; Trauner, M; Peck-Radosavljevic, M; Reiberger, T; Mandorfer, M: Liver fibrosis assessment and treatment initiation within a systematic screening program among HIV/HIV-coinfected patients
A41
Dax, K; Reiter, S; Pohanka, E; Pieringer, H; Hayat-Khayyati, A: Vascular function in hepatitis C patients – a cross sectional study
A42
Fritz, T; Hametner, S; Ziachehabi, A; Schöfl, R; Maieron, A: Der VITRO Score als nichtinvasiver, diagnostischer und prädiktiver Parameter für das Auftreten von Ösophagusvarizen in Patienten mit kompensierter Leberzirrhose
A43
Grabherr, F; Grander, C; Wieser, V; Mayr, L; Enrich, B; Reiter, A; Sangineto, M; Viveiros, A; Zoller, H; Moschen, A; Adolph, T; Tilg, H: Targeting the Role of IL-37 in ALD
A44
Grander, C; Grabherr, F; Enrich, B; Tilg, H: Akkermansia muciniphila tend to influence experimental non-alcoholic steatohepatitis
A45
Gschwantler, M; Ferenci, P; Bauer, B; Laferl, H; Bamberger, T; Stauber, R; Graziadei, I; Teskey, A; Maieron, A: Burden of disease in patients with chronic hepatitis C in the Austrian REAL Study
A46
Halilbasic, E; Hofer, H; Munda, P; Owens-Grillo, J; Smoot Malecha, E; MacConell, L; Trauner, M: Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Extension with Obeticholic Acid in Austrian and German Patients with Primary Biliary Cholangitis
A47
Hambauer, J; Nömeyer, R; Spöttl, P; Hofer, H: Periumbilicale und submammäre Hautembolien als seltene Komplikation nach transarterieller Chemoembolisation eines hepatocellulären Karzinoms: Fallbericht und Literaturübersicht
A48
Hametner, S; Schöfl, R; Maieron, A: LiMAx – real world Daten, ein erster Überblick
A49
Hametner, S; Schöfl, R; Hametner, S; Kivaranovic, D; Maieron, A: Regression of cirrhosis and fibrosis in patients with sustained virological response (SVR) after direct acting antiviral therapy (DAA) due to chronic hepatitis C
A50
Horvath, A; Grande, P; Rainer, F; Blesl, A; Meinitzer, A; Leber, B; Schmerböck, B; Komarova, I; Fickert, P; Stiegler, P; Wagner, M; Stadlbauer, V: FGF21 in acute and chronic alcohol consumption
A51
Horvath, A; Rainer, F; Bashir, M; Leber, B; Schmerböck, B; Grønbæk, H; Madl, T; Fickert, P; Stiegler, P; Stadlbauer, V: Protonenpumpenhemmer bei Leberzirrhose: Einfluss auf Dysbiose, Darmpermeabilität, Inflammation und Mortalität
A52
Kozbial, K; Moser, S; Al-Zoairy, R; Schwarzer, R; Datz, C; Stauber, R; Laferl, H; Srasser, M; Beinhardt, S; Stättermayer, A; Gschwantler, M; Zoller, H; Maieron, A; Hofer, H; Steindl-Munda, P; Ferenci, P: Long-term follow up of patients with advanced chronic hepatitis C after successful treatment with interferon/ribavirin-free combination of direct acting antivirals
A53
Leber, B; Horvath, A; Schmerböck, B; Tawdrous, M; Streit, A; Posch, A; Fickert, P; Spindelböck, W; Stiegler, P; Stauber, RE; Stadlbauer, V: Neutrophil phagocytic capacity in chronic hepatitis C improves under direct acting antivirals
A54
Mandorfer, M; Schwabl, P; Paternostro, R; Pomej, K; Thaler, J; Ay, C; Fritzer-Szekeres, M; Quehenberger, P; Trauner, M; Peck-Radosavljevic, M; Reiberger, T; Ferlitsch, A: Von Willebrand factor antigen is linked to bacterial translocation, inflammation, as well as procoagulant imbalance and predicts complications of cirrhosis independently of portal hypertension severity
A55
Mattes, S; Hametner, S; Ziachehabi, A; Schöfl, R; Maieron, A: Relapse rate, frequencies of different Resistance associated variants (RAV) and retreatment outcome of HCV patients from a large Austrian treatment centre
A56
Moser, S; Kozbial, K; Laferl, H; Gutic, E; Beinhardt, S; Reiberger, T; Ferenci, P; Gschwantler, M: Sofosbuvir/ledipasvir in combination with ribavirin shows high SVR12-rates in genotype-3 infected patients – experience from an austrian real world cohort
A57
Moser, S; Schütz, A; Marchart, K; Schwanke, C; Kalchbrenner, D; Rechberger, G; Schubert, R; Luhn, J; Gutic, E; Haltmayer, H; Gschwantler, M: Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy
A58
Nowak, M: Fulminantes Leberversagen unklarer Ätiologie
A59
Pinter, M; Weinmann, A; Wörns, M; Hucke, F; Bota, S; Marquardt, JU; Duda, DG; Jain, RK; Galle, PR; Trauner, M; Peck-Radosavljevic, M; Sieghart, W: Use of inhibitors of the renin angiotensin system is associated with longer survival in patients with hepatocellular carcinoma
A60
Rainer, F; Horvath, A; Sandahl, TD; Leber, B; Schmerböck, B; Blesl, A; Stauber, R; Fickert, P; Stiegler, P; Møller, HJ; Grønbæk, H; Stadlbauer, V: Löslicher Mannose-Rezeptor und sCD163 bei PatientInnen mit Leberzirrhose als Biomarker für Mortalität und Auftreten von Komplikationen
A61
Reiter, S; Dax, K; Berg, J; Bamberger, T; Pohanka, E; Hayat-Khayyati, A: Treatment of Rare Inter-genotypic RF2k/1b Hepatitis C Virus Infection with Sustained Virological Response
A62
Riedl, F; Watzl, P; Ristl, D; Pfisterer, N; Scheiner, B; Bucsics, T; Schwabl, P; Mandorfer, M; Ferlitsch, A; Trauner, M; Reiberger, T: Outcome and survival after acute variceal bleeding in patients with liver cirrhosis
A63
Schaefer, B; Finkenstedt, A; Viveiros, A; Tilg, H; Zoller, H: Comparison of Heterozygous Alpha-1 Antitrypsin Deficiency in Patients with Liver Cirrhosis and Transplant Recipients with the General Population and Liver Donors
A64
Scheiner, B; Stammet, P; Pokorny, S; Bucsics, T; Schwabl, P; Brichta, A; Thaler, J; Lampichler, K; Ba-Ssalamah, A; Pabinger, I; Ay, C; Ferlitsch, A; Trauner, M; Mandorfer, M; Reiberger, T: Anticoagulation in non-malignant portal vein thrombosis is associated with improved hepatic function
A65
Schwabl, P; Königshofer, P; Brusilovskaya, K; Szodl, A; Lampach, D; Supper, P; Bauer, D; Huber, J; Trauner, M; Reiberger, T: Comparison of stimulators versus activators of soluble guanylyl cyclase (sGC) to phosphodiesterase-5 (PDE5) inhibition in biliary cirrhosis and portal hypertension
A66
Schwabl, P; Brusilovskaya, K; Königshofer, P; Supper, P; Bauer, D; Riedl, F; Rohr-Udilova, N; Hayden, H; Aschauer, S; Bonderman, D; Oberhuber, G; Podesser, B; Peck-Radosavljevic, M; Trauner, M; Reiberger, T: Molecular effects of the soluble guanylyl cyclase stimulator Riociguat in experimental cirrhosis and impact on transaminases in patients
A67
Stauber, R; Spindelböck, W; Rainer, F; Douschan, P; Lackner, C: Limited value of clinical criteria for diagnosis of alcoholic steatohepatitis (ASH)
A68
Staufer, K; Rasoul-Rockenschaub, S; Soliman, T; Berlakovich, G: Wartelistenmortalität und Post-Transplant-Überleben in PatientInnen mit Cholestatischer Lebererkrankung – 24-Jahre Zentrumspraxis
A69
Teufelhart, M; Hofer, H; Haslacher, H; Winker, R; Meyer, B; Ferenci, P; Mehl, B; Rabitsch, C; Nistler, S; Trauner, M; Scherzer, T: A prospective study to evaluate the efficacy of a standardized low calorie diet (HEPAFAST®) according to PNPLA3 genotype in patients with Non Alcoholic Fatty Liver Disease (NAFLD) – 2 months data (interim analysis)
A70
Teufelhart, M; Rabitsch, C; Mehl, B; Meyer, B; Winker, R; Scherzer, T: Use of FibroScan® to diagnose liver diseases in Austrian bank employees and correlation of FibroScan® CAP with Fatty Liver Index (FLI) – where is the optimal FLI cut off?
A71
Traussnigg, S; Kienbacher, C; Halilbasic, E; Hofer, H; Munda, P; Wolzt, M; Trauner, M: Efficacy and safety of the non-steroidal farnesoid X receptor agonist PX-104 in patients with non-alcoholic fatty liver disease (NAFLD)
A72
Viveiros, A; Schäfer, B; Finkenstedt, A; Henninger, B; Nachbaur, K; Haubner, R; Decristoforo, C; Tilg, H; Zoller, H: Expanding the clinical and molecular spectrum of ferroportin disease
A73
Viveiros, A; Finkenstedt, A; Schäfer, B; Lehner, K; Tobiasch, M; Tilg, H; Zoller, H: Transferrin: a predictor of survival in early stage liver cirrhosis
A74
Weitersberger, M; Hametner, S; Ziachehabi, A; Gerstl, S; Függer, R; Schöfl, R; Schwarzer, R; Maieron, A: Therapie der malignen Gallengangsobstruktion – Eine retrospektive Analyse im Ordensklinikum Elisabethinen Linz
A75
Weitersberger, M; Hametner, S; Fritz, T; Schöfl, R; Maieron, A: Hepatitis C bei Suchtpatienten – Diagnose, Therapie und Nachbetreuung